Item 8.01 Other Events.

On November 13, 2012, Insmed Incorporated (the "Company") issued a press release announcing the completion of target enrollment for the Company's pivotal CLinical Evaluation of ARIKACE phase 3 study (CLEAR-108) of ARIKACEŽ (liposomal amikacin for inhalation) in Europe and Canada for Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release issued by Insmed Incorporated dated November 13, 2012.

---